GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Shiller PE Ratio

XNCR (Xencor) Shiller PE Ratio : (As of Apr. 27, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Xencor Shiller PE Ratio Historical Data

The historical data trend for Xencor's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Shiller PE Ratio Chart

Xencor Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xencor Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xencor's Shiller PE Ratio

For the Biotechnology subindustry, Xencor's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Shiller PE Ratio falls into.


;
;

Xencor Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xencor's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Xencor's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.62/133.1571*133.1571
=-0.620

Current CPI (Dec. 2024) = 133.1571.

Xencor Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.190 99.621 -0.254
201506 -0.220 100.684 -0.291
201509 -0.250 100.392 -0.332
201512 0.190 99.792 0.254
201603 -0.160 100.470 -0.212
201606 1.130 101.688 1.480
201609 -0.200 101.861 -0.261
201612 -0.210 101.863 -0.275
201703 -0.330 102.862 -0.427
201706 -0.170 103.349 -0.219
201709 -0.480 104.136 -0.614
201712 -0.250 104.011 -0.320
201803 -0.620 105.290 -0.784
201806 -0.460 106.317 -0.576
201809 0.050 106.507 0.063
201812 -0.320 105.998 -0.402
201903 1.380 107.251 1.713
201906 -0.280 108.070 -0.345
201909 -0.180 108.329 -0.221
201912 -0.470 108.420 -0.577
202003 -0.140 108.902 -0.171
202006 -0.610 108.767 -0.747
202009 -0.220 109.815 -0.267
202012 -0.240 109.897 -0.291
202103 -0.040 111.754 -0.048
202106 0.870 114.631 1.011
202109 -0.690 115.734 -0.794
202112 1.210 117.630 1.370
202203 0.390 121.301 0.428
202206 -0.570 125.017 -0.607
202209 -0.550 125.227 -0.585
202212 -0.200 125.222 -0.213
202303 -1.020 127.348 -1.067
202306 -0.370 128.729 -0.383
202309 -0.400 129.860 -0.410
202312 -0.310 129.419 -0.319
202403 -1.200 131.776 -1.213
202406 -1.090 132.554 -1.095
202409 -0.720 133.029 -0.721
202412 -0.620 133.157 -0.620

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xencor  (NAS:XNCR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Xencor Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor Business Description

Traded in Other Exchanges
N/A
Address
465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Executives
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604